Free Trial

NovoCure Q1 2024 Earnings Report

NovoCure logo
$30.51 +0.66 (+2.21%)
(As of 12/3/2024 06:07 PM ET)

NovoCure Earnings Headlines

NovoCure (NASDAQ:NVCR) Raised to Outperform at Evercore ISI
The Crypto Secret Wall Street Doesn’t Want You to Know
The Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech giants are quietly integrating it. Venture capitalists are scrambling to invest.
NovoCure’s PANOVA-3 Trial Success Boosts Oncology Prospects
Wedbush Reiterates Neutral Rating for NovoCure (NASDAQ:NVCR)
See More NovoCure Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like NovoCure? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NovoCure and other key companies, straight to your email.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

View NovoCure Profile

More Earnings Resources from MarketBeat